West Pharmaceutical Services stock holds a Moderate Buy rating

West Pharmaceutical Services (US9523901012) stock held a Moderate Buy consensus on September 19, 2026, with MarketBeat putting the average price target at USD 379.08. The shares closed at USD 361.82 on September 18, 2026, after a daily decline of 1.30 percent.

Analysts stay constructive

According to MarketBeat, West Pharmaceutical Services had 11 Buy ratings and 3 Hold ratings on September 19, 2026, which keeps the stock at a Moderate Buy consensus. The same analyst overview puts the average target at USD 379.08, only 4.8 percent above the latest close.

That valuation gap is not large. MarketBeat also lists a 52-week range of USD 223.83 to USD 386.00, so the current price still sits 6.3 percent below the high and 61.9 percent above the low.

Operational pressure points

As ad hoc news reported on September 19, 2026, Simply Wall St pointed to a cyber incident, tariff-related cost inflation and Annex 1 compliance work as the main operating variables around the name. The same report says West Vantage weakness has added pressure, while about 340 Annex 1 projects support the longer-term case.

MarketBeat says West Pharmaceutical Services reported USD 2.37 in EPS for the quarter ended July 23, 2026, beating the consensus estimate of USD 2.08 by USD 0.29. The same page says quarterly revenue was up 13.8 percent year over year, a useful reminder that the business still grows even as investors debate execution risk.

Price and size

West Pharmaceutical Services stock ended September 18, 2026, at USD 361.82 on the NYSE, with volume of 1.46 million shares and market capitalization of USD 25.47 billion. The stock was also trading 31.3 percent above its start-of-2026 level of USD 275.53, according to MarketBeat.

More news and analyses on West Pharmaceutical Services stock